Siltuximab

Last Updated: 06/30/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 310 publications

Successful treatment of idiopathic multicentric Castleman disease with TAFRO and kidney involvement: case report and literature review.

Successful treatment of idiopathic multicentric Castleman disease with TAFRO and kidney involvement: case report and literature review.

Journal: Renal failure

Published: June 18, 2026

Updates in the pharmacologic management of various Castleman disease subtypes: A comprehensive review.

Updates in the pharmacologic management of various Castleman disease subtypes: A comprehensive review.

Journal: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners

Published: May 26, 2026

CD19/CD22 bivalent CAR T cells in children, adolescents and young adults with B-ALL: final phase 1 trial results.

CD19/CD22 bivalent CAR T cells in children, adolescents and young adults with B-ALL: final phase 1 trial results.

Journal: Journal for immunotherapy of cancer

Published: May 21, 2026

Intensive Administration of Siltuximab Monotherapy for Idiopathic Multicentric Castleman Disease-TAFRO Subtype:Report of One Case.

Intensive Administration of Siltuximab Monotherapy for Idiopathic Multicentric Castleman Disease-TAFRO Subtype:Report of One Case.

Journal: Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae

Published: May 15, 2026

Treatment of Castleman disease from the perspective of the year 2026.

Treatment of Castleman disease from the perspective of the year 2026.

Journal: Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti

Published: May 04, 2026

Idiopathic multicentric Castleman disease in a patient with an IgG4-related disease phenotype.

Idiopathic multicentric Castleman disease in a patient with an IgG4-related disease phenotype.

Journal: BMJ case reports

Published: April 21, 2026

Real-World Usage and Outcomes of Different Siltuximab Dosing Frequency in Idiopathic Multicentric Castleman Disease.

Real-World Usage and Outcomes of Different Siltuximab Dosing Frequency in Idiopathic Multicentric Castleman Disease.

Journal: American journal of hematology

Published: April 18, 2026

Serum proteomics reveals distinct phenotypic signatures to IL-6 blockade between two immunotherapies.

Serum proteomics reveals distinct phenotypic signatures to IL-6 blockade between two immunotherapies.

Journal: bioRxiv : the preprint server for biology

Published: April 10, 2026

Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis Following CAR T-Cell Therapy: Results of a Real-World Study.

Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis Following CAR T-Cell Therapy: Results of a Real-World Study.

Journal: Cancers

Published: April 05, 2026

Early intervention for high-risk smoldering multiple myeloma (SMM).

Early intervention for high-risk smoldering multiple myeloma (SMM).

Journal: The Cochrane database of systematic reviews

Published: March 18, 2026

Tocilizumab but not Siltuximab prevents systemic inflammation in a humanized mouse model.

Tocilizumab but not Siltuximab prevents systemic inflammation in a humanized mouse model.

Journal: Frontiers in immunology

Published: February 19, 2026

Correction: Siltuximab as a first-line therapy for idiopathic multicentric Castleman disease: a retrospective analysis based on the SiMuLa study of the Italian regional network.

Correction: Siltuximab as a first-line therapy for idiopathic multicentric Castleman disease: a retrospective analysis based on the SiMuLa study of the Italian regional network.

Journal: Frontiers in oncology

Published: February 16, 2026

Showing 1-12 of 310

Last Updated: 06/30/2026